Procept Biorobotics Corp PRCT

$17.16 +0.14 (0.82%)

Valuation

Market cap
982,822,000
Revenue TTM
$308,050,000
Net income TTM
$-95,570,000
PE ratio
0.00
Forward PE
—
Profit margin
-31.02%
Debt to equity
0.15

Trading

Volume
1,240,800
Avg volume
1,448,524
Day's range
$16.95 – $17.91
Shares out
57,274,000
Stochastic %K
17%
Beta
0.92
Analysts
Sell
Price target
$21.64

Price

Company profile

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquabl...

Show more

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Industry
Medical Devices
Sector
Healthcare
Phone
650 232 7200
Website
https://www.procept-biorobotics.com
Address
150 Baytech Drive, San Jose, United States

Latest news

Stocktwits

Startersorder Oct 2, 7:38 PM
$PRCT cheapest “growth” medtech company in the market. Trading of ridiculously low multiple for a company growing 20%. By Q4 growth will by up massively. Do your research……..
0 replies
Startersorder Oct 2, 4:30 PM
$PRCT based on my analysis, PRCT is currently the cheapest “growth” med tech company. In addition, the class action (which will have an uphill task to prove their case - if it is not dismissed entirely) will get $0-5m settlement (covered by insurance for PRCT). Any payout looks irrelevant relative to PRCT cash position = non event. I think we will see around 50-60% YOY growth for Q4. It looks a bargain down here.
0 replies
Easymoney48 Sep 29, 7:06 PM
$PRCT be careful the swing idiots see a double bottom.
0 replies
AStateofTrance7 Sep 29, 6:31 PM
$PRCT
0 replies
Startersorder Sep 28, 12:27 PM
$PRCT market cap at close on Friday $979M. Strip out the cash $227M and you get EV $752M. With 2026 rev at $400M and 2027 around $500, EBITDA positive in Q4 2026, Cancer treatment online in 2028, over 13,000+ procedures per quarter, margins of 65%……… this must be the cheapest med tech company out there. Someone has to buy this business, they will make a fortune by 2028. Makes no sense to be trading @ $17
1 replies
BioTechHealthX Sep 26, 1:29 PM
$PRCT PROCEPT’s second-quarter revenue rose 19% to $94.5 million, but its net loss widened to $26.9 million. Here’s the tension behind this focused medical robotics stock. https://biotechhealthx.com/biotech-news/procept-prct-has-a-robot-a-growth-story-and-a-26-9m-problem/
0 replies
waugusti Sep 25, 11:31 AM
$PRCT now is a good time to go long. Buyout in 2027.
0 replies
BioTechHealthX Sep 25, 7:28 AM
$ISRG $PRCT $MDT $SYK $ZBH Medical robots do far more than assist surgeons. This countdown covers surgical robotics, pharmacy automation and robotic radiotherapy stocks for 2026. https://biotechhealthx.com/biotech-news/top-5-medical-robotics-stocks-to-buy-today/
0 replies